Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive crawled date : 2021 - 09 - 17 save search
Duck Creek Technologies Positioned as a Leader in Gartner ® 2021 Magic Quadrant ™ for P&C Platforms, North America, Seven Times in a Row
Published: 2021-09-17 (Crawled : 17:00) - globenewswire.com
IT | $440.38 -2.05% 0.0% 450K
|
Commercial Services
|
| O: -0.26%
H: 0.0%
C: 0.0%
DCT | $18.99 0.0% 0
|
Technology Services
|
| O: 0.32%
H: 0.0%
C: 0.0%
3D Printing Market Forecast Predicts Positive Impact due to COVID-19 Pandemic|Technavio Reports Covering 800 Technologies
Published: 2021-09-17 (Crawled : 14:00) - prnewswire.com
XRAY A | $30.5 0.2% 0.2% 1.8M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
covid positive
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction
Published: 2021-09-17 (Crawled : 13:15) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -1.14%
H: 0.0%
C: 0.0%
positive therapy chmp her2+ her2- her2 nivolumab
Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor
Published: 2021-09-17 (Crawled : 13:00) - biospace.com/
DCPH | $14.69 3.23% 3.13% 390K
|
Health Technology
|
| O: 1.04%
H: 0.0%
C: 0.0%
treatment test positive gastrointestinal chmp
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
Published: 2021-09-17 (Crawled : 13:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
positive therapy cancer breast cancer chmp keytruda
Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer
Published: 2021-09-17 (Crawled : 13:00) - biospace.com/
CORT | $22.97 1.37% 1.35% 920K
|
Health Technology
|
| O: -3.39%
H: 0.0%
C: 0.0%
phase 2 positive results positive results cancer ovarian cancer trial
Gritstone Announces Positive Clinical Data with GRANITE (Individualized Neoantigen Immunotherapy Program) during ESMO 2021 and Launch of Randomized Clinical Trial Program in Colorectal Cancer with Registrational Intent
Published: 2021-09-17 (Crawled : 12:00) - globenewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -1.14%
H: 0.0%
C: 0.0%
GRTS | $0.7414 -0.31% -0.31% 1.5M
|
Health Technology
|
| O: 3.4%
H: 0.0%
C: 0.0%
immunotherapy positive therapy cancer colorectal cancer trial program
Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
Published: 2021-09-17 (Crawled : 12:00) - globenewswire.com
BPMC | $86.87 -2.28% -2.34% 800K
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
treatment lung cancer positive cancer chmp
GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Published: 2021-09-17 (Crawled : 12:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
treatment positive chmp ulcerative colitis
TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors
Published: 2021-09-17 (Crawled : 12:00) - globenewswire.com
TCRR 4 | $1.48 3.38% 3.9M
|
Health Technology
|
| O: -21.82%
H: 0.0%
C: 0.0%
treatment solid tumors ongoing phase 1 positive results trial cel
Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Published: 2021-09-17 (Crawled : 01:00) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: 0.0%
treatment positive therapy results phase 3 trial cell carcinoma
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
GRFX | $0.2116 -1.58% 7.28% 40K
|
n/a
LYT | $4.22 4.72% 5.62% 1.4M
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.